Clinical Trials at Benefis Sletten Cancer Institute

As of July 2026, 87 paid clinical trials are recruiting at Benefis Sletten Cancer Institute in Great Falls, Montana. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 16, 2026.

Filter results

Filter results

State

City

Facility

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

87 clinical trials at Benefis Sletten Cancer Institute

·Clear filters·↓ Download CSV

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

for High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements

86 locations incl. Tucson

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06649812·Phase 2·Recruiting

Apply to this trial

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

for Metastatic Nasopharyngeal Carcinoma

Drug: Relatlimab

83 locations incl. Dublin

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06029270·Phase 2·Recruiting

Apply to this trial

Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy

for Recurrent Non-Muscle Invasive Bladder Carcinoma

58 locations incl. Birmingham

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT07000084·Phase 3·Recruiting

Apply to this trial

Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)

for Core Binding Factor Acute Myeloid Leukemia

Drug: Venetoclax

23 locations incl. Coeur d'Alene

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18 - 59

Code: NCT06917911·Phase 2·Recruiting

Apply to this trial

Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases

for Brain Metastases

73 locations incl. Tucson

Sponsor: Canadian Cancer Trials Group

Sex: All·Age: 18+

Code: NCT03550391·Phase 3·Recruiting

Apply to this trial

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

for Anatomic Stage II Breast Cancer AJCC v8

Drug: Ribociclib

61 locations incl. Jonesboro

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT07391774·Phase 3·Recruiting

Apply to this trial

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

for Lung Non-Small Cell Carcinoma

Drug: Atezolizumab

10 locations incl. Coeur d'Alene

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT07388524·Phase 3·Recruiting

Apply to this trial